News
AstraZeneca's Fasenra has been cleared for use by the NHS in England as an add-on treatment for the rare autoimmune disease ...
Arab Finance: GlaxoSmithKline Egypt (GSK–Egypt) logged consolidated net profits for controlling interest of EGP 65.060 ...
10h
TipRanks on MSNGSK Expands Share Buyback Programme with New Purchase
GlaxoSmithKline has announced the purchase of 306,478 of its own ordinary shares as part of its ongoing buyback programme. This transaction, executed through Merrill Lynch International, is part of a ...
In late April, the FDA notified SCYNEXIS that the clinical hold on ibrexafungerp had been lifted and concluded that the Phase 3 MARIO study could resume. The MARIO study is a Phase 3 trial evaluating ...
President Donald Trump has called on 17 pharmaceutical companies to implement most-favored-nation drug pricing in the next 60 days.
The global Musculoskeletal Oncology Therapeutics Market is projected to grow from USD 2.2 billion in 2025 to USD 3.3 billion ...
Spero Therapeutics, Inc. (NASDAQ: SPRO) Q2 2025 Earnings Call Transcript August 12, 2025 Spero Therapeutics, Inc. beats ...
HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
2d
TipRanks on MSNGSK Executives Acquire Shares Under Reward Plan
GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...
The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results